Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592943 · ClinicalTrials.gov registry record · Phase 1
PET Study Examining the Dopaminergic Activity of Armodafinil in Adults
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00592943: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00592943 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00592943, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The specific aims of this study are 1) to document the Dopamine Transporter (DAT) receptor occupancy of armodafinil using positron emission tomography (PET) scanning with C-11 altropane as the ligand and 2) to document the increased intrasynaptic dopamine produced by armodafinil using PET scanning with C-11 raclopride as the ligand. We hypothesize that DAT occupancy will be low with armodafinil; less than the DAT occupancy produced by therapeutic doses of methylphenidate. We also hypothesize that increases in intrasynaptic dopamine will be relatively low with armodafinil.
Interventions
- DRUG armodafinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00592943
The ClinicalTrials.gov registry entry for NCT00592943 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which armodafinil is the first listed.
NCT00592943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00592943 about?
NCT00592943 is a clinical study titled "PET Study Examining the Dopaminergic Activity of Armodafinil in Adults". The specific aims of this study are 1) to document the Dopamine Transporter (DAT) receptor occupancy of armodafinil using positron emission tomography (PET) scanning with C-11 altropane as the ligand and 2) to document the increased intrasynaptic dopamine produced by armodafinil using PET scanning w...
What is the current status of trial NCT00592943?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2007-10. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00592943?
The interventions under investigation include: armodafinil (DRUG).
Who is sponsoring clinical trial NCT00592943?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.